Protagenic Therapeutics (PTIX)
OTHER OTC:PTIX
Top Page
No summary available
Positive Factors
Clinical Trial Progress
Advancing clinical trials for PT00114 indicates progress in drug development, potentially leading to new revenue streams upon successful commercialization.
Negative Factors
Financial Instability
Persistent financial losses and lack of revenue highlight challenges in achieving financial stability, increasing reliance on external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical Trial Progress
Advancing clinical trials for PT00114 indicates progress in drug development, potentially leading to new revenue streams upon successful commercialization.
Read all positive factors
Protagenic Therapeutics (PTIX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.06M
Dividend YieldN/A
Average Volume (3M)102.28K
Price to Earnings (P/E)―
Beta (1Y)-1.92
Revenue GrowthN/A
EPS Growth64.85%
CountryUS
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-15.83
Shares Outstanding1,810,208
10 Day Avg. Volume80,054
30 Day Avg. Volume102,276
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.05
Price to Sales (P/S)0.00
P/FCF Ratio-0.61
Enterprise Value/Market Cap1.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-53.23
Enterprise Value/Ebitda-0.25
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Protagenic Therapeutics Business Overview & Revenue Model
Company Description
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-te...
How the Company Makes Money
Protagenic Therapeutics primarily makes money through the development and commercialization of its neuropeptide-based therapeutics. The company seeks to generate revenue by advancing its drug candidates through clinical trials, obtaining regulator...
Protagenic Therapeutics Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -37.72K | -50.29K | -28.22K | -30.00 | 0.00 |
| EBITDA | -8.02M | -5.47M | -4.50M | -3.42M | -4.14M |
| Net Income | -5.16M | -5.53M | -5.00M | -3.56M | -4.52M |
Balance Sheet | |||||
| Total Assets | 2.13M | 1.96M | 4.32M | 8.04M | 11.06M |
| Cash, Cash Equivalents and Short-Term Investments | 2.21M | 1.84M | 4.06M | 7.98M | 10.37M |
| Total Debt | 3.16M | 0.00 | 0.00 | 344.23K | 318.43K |
| Total Liabilities | 6.82M | 942.76K | 655.25K | 1.12M | 1.12M |
| Stockholders Equity | -2.39M | 1.01M | 3.67M | 6.92M | 9.94M |
Cash Flow | |||||
| Free Cash Flow | -4.14M | -4.22M | -3.85M | -2.00M | -2.80M |
| Operating Cash Flow | -4.14M | -4.22M | -3.70M | -1.99M | -2.80M |
| Investing Cash Flow | 943.18K | 2.80M | 4.78M | 1.60M | -9.91M |
| Financing Cash Flow | 4.51M | 1.96M | 0.00 | 0.00 | 12.58M |
Protagenic Therapeutics Technical Analysis
Negative
0.55
Price Trends
0.52
Positive
0.89
Negative
2.05
Negative
Market Momentum
0.01
Positive
47.55
Neutral
40.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PTIX, the sentiment is Negative. The current price of 0.55 is below the 20-day moving average (MA) of 0.62, above the 50-day MA of 0.52, and below the 200-day MA of 2.05, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 47.55 is Neutral, neither overbought nor oversold. The STOCH value of 40.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PTIX.
Protagenic Therapeutics Risk Analysis
Protagenic Therapeutics disclosed 59 risk factors in its most recent earnings report. Protagenic Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Protagenic Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $1.06M | -0.49 | ― | ― | ― | 64.85% | |
| ― | $2.61M | -0.17 | -168.95% | ― | ― | 90.27% | |
40 Underperform | $185.00M | -0.36 | -2323.94% | ― | ― | 52.39% | |
| ― | $755.29K | -1.82 | -263.57% | ― | -34.58% | 96.41% |
* Healthcare Sector Average
PTIX
Protagenic Therapeutics
0.55
-3.48
-86.35%
OGEN
Oragenics
0.68
-4.91
-87.81%
KALA
KALA BIO
0.22
-3.31
-93.71%
KTTA
Pasithea Therapeutics Corp
0.76
-0.57
-42.80%
ONCO
Onconetix
0.80
-26.74
-97.10%
Protagenic Therapeutics Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
Protagenic Therapeutics Faces Nasdaq Delisting Notice
Negative
Nov 26, 2025
On November 20, 2025, Protagenic Therapeutics received a notification from Nasdaq indicating non-compliance with listing rules due to insufficient stockholders’ equity and delayed filing of a quarterly report. The company plans to appeal the...
Executive/Board Changes
Jennifer Chao Resigns from Protagenic Therapeutics Board
Neutral
Nov 5, 2025
On November 3, 2025, Jennifer Chao resigned from the Board of Directors of Protagenic Therapeutics, Inc., with no disagreements reported between her and the company....
Business Operations and StrategyLegal ProceedingsM&A Transactions
Protagenic Therapeutics Seeks Rescission of Share Agreement
Negative
Oct 31, 2025
On October 28, 2025, Protagenic Therapeutics, Inc. filed a Verified Complaint in the Delaware Chancery Court seeking rescission of the Share Exchange Agreement with Phytanix Bio, Inc., dated May 15, 2025. The company alternatively seeks damages an...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―